Targeting 5-HT receptors for the treatment of obesity

Current Opinion in Pharmacology

Volumn 11, Issue 1, 2011, Pages 52-58

  Sargent, Bruce J ^a   Henderson, Alan J ^a  

^a ALBANY MOLECULAR RESEARCH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIMIDINYL]BENZENESULFONAMIDE; AMR SIX 1; BIOVITRUM; DEXFENFLURAMINE; ESTEVE; FENFLURAMINE; LORCASERIN; PHENTERMINE; PLACEBO; PRX 07034; SEROTONIN; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN RECEPTOR; SIBUTRAMINE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG TARGETING; FOOD INTAKE; HUMAN; LOW DRUG DOSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QT PROLONGATION; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE;

EID: 79953718446     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2011.01.005     Document Type: Review

References (55)

1. D.W. Haslam, and W.P. James Obesity Lancet 366 2005 1197 1209 (Pubitemid 41393598)
2. J.P. Després Dyslipidaemia and obesity Balliere's Clin Endocrinol Metab 8 1994 629 660
3. I.S. Okosun, K.M.D. Chandra, S. Choi, J. Christman, G.E.A. Dever, and T.E. Prewitt Hypertension and type 2 diabetes comorbidity in adults in the United States: risk of overall and regional adiposity Obes Res 9 2001 1 9 (Pubitemid 33603824)
4. H. Yatsuka, A.R. Folsom, K. Yamagishi, K.E. North, F.L. Brancati, and J. Stevens Race- and sex-specific associations of obesity measures with ischemic stroke incidence in the Atherosclerosis Risk in Communities (ARIC) study Stroke 4 2010 417 425
5. G.A. Colditz, W.C. Willett, A. Rotnitzky, and J.E. Manson Weight gain as a risk factor for clinical diabetes in women Ann Intern Med 122 1995 481 486
6. L. Garfinkel Overweight and cancer Ann Intern Med 103 1985 1034 1036 (Pubitemid 16211927)
7. M. Poulain, M. Doucet, G.C. Major, V. Drapeau, F. Séris, L.-P. Boulet, A. Tremblay, and F. Maltais The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies Can Med Assoc J 174 2006 1293 1299
8. E.M. Badley, and H. Ansari Arthritis and arthritis-attributable activity limitations in the United States and Canada: a cross-border comparison Arthritis Care Res 62 2010 308 315
9. L.L. Boland, A.R. Folsom, and W.D. Rosamond Hyperinsulinemia, dyslipidemia, and obesity as risk factors for hospitalized gallbladder disease. A prospective study Ann Epidemiol 12 2002 131 140 (Pubitemid 34204117)
10. C.D. Sjostrom, L. Lissner, and L. Sjostrom Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study Obes Res 5 1997 519 530 (Pubitemid 127702673)
11. J.C. Seidell, W.M. Verschuren, E.M. Van-Leer, and D. Kromhout Overweight, underweight, and mortality: a prospective study of 48,287 men and women Arch Intern Med 156 1996 958 963 (Pubitemid 26149122)
12. B.C.T. Field, O.B. Chaudhri, and S.R. Bloom Obesity treatment: novel peripheral targets Br J Clin Pharmacol 68 2009 830 843
13. J. Torgerson, J. Hauptman, M. Boldrin, and L. Sjöström XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 27 2004 155 161 (Pubitemid 38196725)
14. B.J. Sargent, and N.A. Moore New central targets for the treatment of obesity Br. J Clin Pharmacol 68 2009 852 860 A review of CNS targets implicated in the treatment of obesity. Addresses serotonergic mechanisms as well as other approaches.
15. W. McNeely, and K.L. Goa Sibutramine: a review of its contribution to the management of obesity Drugs 56 1998 1093 1124 (Pubitemid 29010230)
16. S.P. Vickers, and C.T. Dourish Serotonin receptor ligands and the treatment of obesity Curr Opin Investig Drugs 5 2004 377 388
17. P.G. Clifton, and G.A. Kennett Monoamine receptors in the regulation of feeding. Behaviour and energy balance CNS Neurol Disord Drug Targets 5 2006 293 312 Review of the role of monoaminergic receptors in controling food intake and lowering body weight. There is a large section devoted to serotonin receptors, where the role of all the serotonin receptors on food intake and body weight is discussed. (Pubitemid 43881012)
18. D.A. Lam, A.S. Garfield, O.J. Marston, J. Shaw, and L.K. Heisler Brain serotonin system in the coordination of food intake and body weight Pharmacol Biochem Behav 97 2010 84 91 Recent review discussing serotonin and receptors that serotonin acts upon within the brain and their effect on food intake and body weight. Many useful resources such as compiled data on knockout mouse studies and effect on feeding behavior on almost all of the serotonin receptors are included.
19. J.E. Blundell Is there a role for serotonin (5-hydroxytriptamine) in feeding? Int J Obesity 1 1977 15 42
20. D.L. Murphy, and K.P. Lesch Targeting the murine serotonin transporter: insights into human neurobiology Nat Rev Neurosci 9 2008 85 96 (Pubitemid 351164876)
21. A. Pringle, K.A. Jennings, S. Line, D.M. Bannerman, S. Higgs, and T. Sharp Mice overexpressing the 5-hydroxytryptamine transporter show no alterations in feeding behaviour and increased non-feeding responses to fenfluramine Psychopharmacology 200 2008 291 300
22. D.T. Wong, L.R. Reid, and P.G. Threlkeld Suppression of food intake in rats by fluoxetine: comparison of enantiomers and effects of serotonin antagonists Pharmacol Biochem Behav 31 1988 475 479 (Pubitemid 19275171)
23. P.U. Dubuc, and C.M. Peterson Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice J Pharmacol Exp Ther 255 1990 976 979
24. J.C.G. Halford, S.C.D. Wanninayake, and J.E. Blundell Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake Pharmacol Biochem Behav 61 1998 159 168 (Pubitemid 28458908)
25. A.S. Ward, S.D. Comer, M. Haney, M.W. Fischman, and R.W. Foltin Fluoxetine-maintained obese humans: effect on food intake and body weight Physiol Behav 66 1999 815 821 (Pubitemid 29281644)
26. P.J. Wellman Norepinephrine and the control of food intake Nutrition 16 2000 837 842
27. A. Balcioglu, and R.J. Wurtman Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid Neuropharmacology 39 2000 2352 2359 (Pubitemid 30642778)
28. 2C agonism as a treatment for 'sick fat' and metabolic disease Expert Rev Cardiovasc Ther 7 2009 1429 1445
29. L.K. Heisler, E.E. Jobst, G.M. Sutton, L. Zhou, E. Borok, Z. Thornton-Jones, H.Y. Liu, J.M. Zigman, N. Balthasar, and T. Kishi Serotonin reciprocally regulates melanocortin neurons to modulate food intake Neuron 51 2006 239 249 (Pubitemid 44063615)
30. A.S. Garfield, and L.K. Heisler Pharmacological targeting of the serotonergic system for the treatment of obesity J Physiol 587 2009 49 60 Overview of the relationship between the serotonergic system and food intake.
31. J.C.G. Halford, J.A. Harrold, E.J. Boyland, C.L. Lawton, and J.E. Blundell Serotonin drugs: effects on appetite expression and use for the treatment of obesity Drugs 67 2007 27 55 Extremely comprehensive review of the serotonin system within the brain and the mechanisms involved in the regulation of food intake. There are informative, detailed discussions on many aspects of serotonergic effects on feeding including the effects of various drugs on both food intake and the behavioral satiety sequence. (Pubitemid 46105086)
32. 6 antagonism in reducing food intake.
33. R.B. Rothman, R.D. Clark, J.S. Partilla, and M.H. Baumann (+)-Fenfluramine and its major metabolite. (+)-norfenfluramine, are potent substrates for norepinephrine transporters J Pharmacol Exp Ther 305 2003 1191 1199 (Pubitemid 36617998)
34. 2C receptor agonists: potential for the treatment of obesity Mol Interv 5 2005 282 291 (Pubitemid 41595460)
35. P.J. Wellman, and T.J. Maher Synergistic interactions between fenfluramine and phentermine Int J Obes Relat Metab Disord 23 1999 723 732 (Pubitemid 29322592)
36. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications Circulation 102 2000 2836 2841
37. 1B) receptor knockout mice have higher body weights than wild types Physiol Behav 74 2001 507 516 (Pubitemid 34076596)
38. 1B receptor agonist CP-94,253 reduces food intake and preserves the behavioural satiety sequence Physiol Behav 60 1996 933 939 (Pubitemid 26284299)
39. S. Boeles, C. Williams, G.M. Campling, E.M. Goodall, and P.J. Cowen Sumatriptan decreases food intake and increases plasma growth hormone in healthy women Psychopharmacology 129 1997 179 182 (Pubitemid 27033674)
40. 1B receptor stimulation enhances cocaine reinforcement J Neurosci 18 1998 10078 10089 (Pubitemid 28543782)
41. 1B receptor to hypoxia-induced pulmonary hypertension Circ Res 89 2001 1231 1239
42. 2C serotonin receptors Nature 374 1995 542 546
43. 2C agonists in treating obesity Expert Opin Invest Drugs 15 2006 257 266 (Pubitemid 43338147)
44. 2C receptor antagonist. Psychopharmacology, doi:10.1007/s00213-010-2106-2.
45. 2C agonist, reduces body weight in obese men and women Obesity 17 2008 494 503
46. S.R. Smith, N.J. Weissman, C.M. Anderson, M. Sanchez, E. Chuang, S. Stubbe, H. Bays, and W.R. Shanahan Multicenter. placebo-controlled trial of lorcaserin for weight management N Engl J Med 363 2010 245 256 Disclosed full clinical trial data for the Phase III study of Lorcaserin. Effects on food intake, body weight and biomarkers predictive of comorbidities are included, as well as observed side effects of the drug.
47. M.A. Valentino, J.E. Lin, and S.A. Waldman Central and peripheral molecular targets for antiobesity pharmacotherapy Nature 87 2010 652 662
48. 6 modulators in obesity models compared to drugs working via different mechanisms is also included.
49. 6 mutant mouse had reduced food intake and body weight compared to wild type when placed on a high fat diet for 11 weeks.
50. M.L. Woolley, J.C. Bentley, A.J. Sleight, C.A. Marsden, and K.C.F. Fone A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze Neuropharmacology 41 2001 210 219 (Pubitemid 32728092)
51. 6 mRNA and receptor levels were determined in different brain regions. (Pubitemid 37532219)
52. M.W. Schwartz, S.C. Woods, D. Porte, R.J. Seeley, and D.G. Baskin Central nervous system control of food intake Nature 404 2000 661 671 (Pubitemid 30205071)
53. V. Setola, and B.L. Roth Why mice are neither minature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants Mol Pharmacol 64 2003 1277 1278 (Pubitemid 37532216)
54. A. Fisas, X. Codony, G. Romero, A. Dordal, J. Giraldo, R. Merce, J. Holenz, D. Heal, H. Buschmann, and P.J. Pauwels Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats Br J Pharmacol 148 2006 973 983 (Pubitemid 44543615)
55. 6 receptor ligands J Med Chem 48 2005 1781 1795 (Pubitemid 40396311)